1536-4844/asset/IBD_left.gif?v=1&s=9aca2b5041534c51cac4bb66560294c77a457a07)
1536-4844/asset/IBD_right.gif?v=1&s=402e3e241083497ae622916e85e47f64138255a4)
Original Article
You have full text access to this OnlineOpen article
B cells exposed to enterobacterial components suppress development of experimental colitis
Article first published online: 25 MAY 2011
DOI: 10.1002/ibd.21769
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Additional Information
How to Cite
Schmidt, E. G. W., Larsen, H. L., Kristensen, N. N., Poulsen, S. S., Claesson, M. H. and Pedersen, A. E. (2012), B cells exposed to enterobacterial components suppress development of experimental colitis. Inflamm Bowel Dis, 18: 284–293. doi: 10.1002/ibd.21769
Publication History
- Issue published online: 10 JAN 2012
- Article first published online: 25 MAY 2011
- Manuscript Accepted: 12 APR 2011
- Manuscript Received: 6 APR 2011
Funded by
- Danish Agency for Science, Technology and Innovation
- Colitis Crohn's Foundation
- Aage and Johanne Louis-Hansen Foundation
- Aase and Ejnar Danielsen Foundation
- Augustinus Foundation
- Lundbeck Foundation
REFERENCES
- 1, , . B-cell suppression of delayed hypersensitivity reactions. Nature. 1974; 251: 550–551.
- 2, . Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol. 1974; 113: 1716–1725.
- 3, , . Regulatory B cells in autoimmune diseases and mucosal immune homeostasis. Autoimmunity. 2011; 44: 58–68.
- 4, . The ‘short’ history of regulatory B cells. Trends Immunol. 2008; 29: 34–40.
- 5, . Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve. 2005; 32: 378–379.
- 6, , . Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007; 56: 2715–2718.
- 7, , , et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008; 57: 714–715.
- 8, , , et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007; 13: 1365–1368.
- 9, , , et al. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med. 1997; 186: 1749–1756.
- 10, , , et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity. 2002; 16: 219–230.
- 11, , , et al. Colitis immunoregulation by CD8+ T cell requires T cell cytotoxicity and B cell peptide antigen presentation. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G485–G492.
- 12, , , et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci U S A. 2005; 102: 2010–2015.
- 13, , , et al. An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells. Gastroenterology. 2004; 126: 1115–1121.
- 14, , , et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002; 3: 944–950.
- 15, , , et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008; 180: 4763–4773.
- 16, , , et al. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol. 2007; 178: 3447–3456.
- 17, , , et al. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med. 1996; 184: 2271–2278.
- 18, , , et al. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med. 2003; 197: 489–501.
- 19, , , et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol. 2001; 167: 1081–1089.
- 20, . Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol. 2007; 179: 7225–7232.
- 21, , . B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci. 2010; 1183: 38–57.
- 22, , , et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol. 2003; 170: 5897–5911.
- 23, , , et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med. 2000; 192: 475–482.
- 24, , , et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 2008; 28: 639–650.
- 25, , , et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008; 118: 3420–3430.
- 26, , , et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol. 2010; 184: 4801–4809.
- 27, , , et al. IL-10-Producing Regulatory B10 Cells Inhibit Intestinal Injury in a Mouse Model. Am J Pathol. 2011; 178: 735–743.
- 28, , , et al. IL-10-producing B220+CD11c- APC in mouse spleen. J Immunol. 2004; 173: 2362–2372.
- 29, , , et al. B cell developmental requirement for the G alpha i2 gene. J Immunol. 2003; 170: 1707–1715.
- 30, , , et al. CD19 expression in B cells is important for suppression of contact hypersensitivity. Am J Pathol. 2007; 171: 560–570.
- 31, , , et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol. 2007; 178: 7868–7878.
- 32, , , et al. TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007; 37: 3040–3053.
- 33, , , et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000; 6: 205–214.
- 34, , , et al. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 508–514.
- 35, , , et al. Enteroantigen-presenting B cells efficiently stimulate CD4(+) T cells in vitro. Inflamm Bowel Dis. 2011; 17: 308–318.
- 36, , , et al. Enteric bacterial antigens activate CD4(+) T cells from scid mice with inflammatory bowel disease. Eur J Immunol. 2001; 31: 23–31.
- 37, , , et al. Demonstration of strong enterobacterial reactivity of CD4+CD25- T cells from conventional and germ-free mice which is counter-regulated by CD4+CD25+ T cells. Eur J Immunol. 2004; 34: 695–704.
- 38, , , et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G135–G146.
- 39, , , et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity. 2010; 33: 279–288.
- 40, , , et al. Chemokines involved in protection from colitis by CD4+CD25+ regulatory T cells. Inflamm Bowel Dis. 2006; 12: 612–618.
- 41, , , et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389: 737–742.
- 42, , , et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004; 172: 5986–5993.
- 43, , , et al. Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A. 2007; 104: 14080–14085.
- 44, , , et al. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol. 2005; 25: 29–40.
- 45, , , et al. CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions. J Immunol. 2010; 184: 4637–4645.
- 46, , , et al. Regulatory B cells shape the development of Th2 immune responses in BALB/c mice infected with Leishmania major through IL-10 production. J Immunol. 2010; 184: 886–894.
- 47, , , et al. Alterations of peripheral blood CD5+ B cells in inflammatory bowel disease. Scand J Gastroenterol. 2009; 44: 172–179.
- 48, , , et al. CD5+ B cells are decreased in peripheral blood of patients with Crohn's disease. Dig Dis Sci. 1992; 37: 1390–1395.
- 49, , , et al. B1a lymphocytes in ulcerative colitis. Int J Colorectal Dis. 2007; 22: 1005–1011.
- 50, , , et al. Cytokine imbalance and autoantibody production in T cell receptor-alpha mutant mice with inflammatory bowel disease. J Exp Med. 1996; 183: 847–856.
- 51, , , et al. Inducible IL-12-producing B cells regulate Th2-mediated intestinal inflammation. Gastroenterology. 2007; 133: 124–136.
- 52, , , et al. Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats. J Exp Med. 1992; 175: 655–659.
- 53, , , et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6: 1123–1132.
- 54, , , et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6: 1133–1141.
- 55, . Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J Immunol. 2006; 176: 5950–5957.
- 56, , , et al. Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood. 2008; 112: 2554–2562.
- 57, , , et al. Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol. 2009; 183: 4094–4102.
- 58, , , et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol. 2006; 177: 5852–5860.
- 59, , , et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009; 10: 1178–1184.